Suppr超能文献

SENP1 通过多种机制诱导前列腺上皮内瘤形成。

SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms.

机构信息

Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

J Biol Chem. 2010 Aug 13;285(33):25859-66. doi: 10.1074/jbc.M110.134874. Epub 2010 Jun 15.

Abstract

SUMOylation has been shown to modulate DNA replication/repair, cell cycle progression, signal transduction, and the hypoxic response. SUMO (small ubiquitin-like modifier)-specific proteases regulate SUMOylation, but how changes in the expression of these proteases contribute to physiological and/or pathophysiological events remains undefined. Here, we show that SENP1 (sentrin/SUMO-specific protease 1) is highly expressed in human prostate cancer specimens and correlates with hypoxia-inducing factor 1alpha (HIF1alpha) expression. Mechanistic studies in a mouse model indicate that androgen-driven expression of murine SENP1 leads to HIF1alpha stabilization, enhanced vascular endothelial growth factor production, and angiogenesis. Further pathological assessment of the mouse indicates that SENP1 overexpression induces transformation of the normal prostate gland and gradually facilitates the onset of high-grade prostatic intraepithelial neoplasia. Consistent with cell culture studies, SENP1 enhances prostate epithelial cell proliferation via modulating the androgen receptor and cyclin D(1). These results demonstrate that deSUMOylation plays a critical role in prostate pathogenesis through induction of HIF1alpha-dependent angiogenesis and enhanced cell proliferation.

摘要

SUMO 化已被证明可以调节 DNA 复制/修复、细胞周期进程、信号转导和低氧反应。SUMO(小泛素样修饰物)特异性蛋白酶调节 SUMO 化,但是这些蛋白酶表达的变化如何导致生理和/或病理生理事件尚不清楚。在这里,我们表明 SENP1(sentrin/SUMO-特异性蛋白酶 1)在人前列腺癌标本中高表达,并与缺氧诱导因子 1alpha(HIF1alpha)表达相关。在小鼠模型中的机制研究表明,雄激素驱动的鼠 SENP1 表达导致 HIF1alpha 稳定,增强血管内皮生长因子的产生和血管生成。对小鼠的进一步病理评估表明,SENP1 过表达诱导正常前列腺的转化,并逐渐促进高级别前列腺上皮内瘤变的发生。与细胞培养研究一致,SENP1 通过调节雄激素受体和细胞周期蛋白 D1 促进前列腺上皮细胞增殖。这些结果表明,去 SUMO 化通过诱导 HIF1alpha 依赖性血管生成和增强细胞增殖在前列腺发病机制中起关键作用。

相似文献

1
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms.
J Biol Chem. 2010 Aug 13;285(33):25859-66. doi: 10.1074/jbc.M110.134874. Epub 2010 Jun 15.
2
SUMO-specific protease 1 promotes prostate cancer progression and metastasis.
Oncogene. 2013 May 9;32(19):2493-8. doi: 10.1038/onc.2012.250. Epub 2012 Jun 25.
3
SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241257490. doi: 10.1177/15330338241257490.
4
Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Urol Oncol. 2013 Nov;31(8):1539-45. doi: 10.1016/j.urolonc.2012.03.007. Epub 2012 Oct 22.
5
SENP1 Interacts with HIF1α to Regulate Glycolysis of Prostatic Carcinoma Cells.
Int J Biol Sci. 2019 Jan 1;15(2):395-403. doi: 10.7150/ijbs.27256. eCollection 2019.
6
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.
Cell. 2007 Nov 2;131(3):584-95. doi: 10.1016/j.cell.2007.08.045.
7
Role of desumoylation in the development of prostate cancer.
Neoplasia. 2006 Aug;8(8):667-76. doi: 10.1593/neo.06445.
8
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis.
J Biol Chem. 2010 Nov 19;285(47):36682-8. doi: 10.1074/jbc.M110.164236. Epub 2010 Sep 14.

引用本文的文献

2
SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration.
Cell Mol Biol Lett. 2024 Dec 2;29(1):146. doi: 10.1186/s11658-024-00665-8.
3
Emerging role of SENP1 in tumorigenesis and cancer therapy.
Front Pharmacol. 2024 Feb 8;15:1354323. doi: 10.3389/fphar.2024.1354323. eCollection 2024.
4
SumoPred-PLM: human SUMOylation and SUMO2/3 sites Prediction using Pre-trained Protein Language Model.
NAR Genom Bioinform. 2024 Feb 7;6(1):lqae011. doi: 10.1093/nargab/lqae011. eCollection 2024 Mar.
5
Discovery of a Dual SENP1 and SENP2 Inhibitor.
Int J Mol Sci. 2022 Oct 11;23(20):12085. doi: 10.3390/ijms232012085.
6
SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone.
Front Cell Dev Biol. 2022 Apr 6;10:889002. doi: 10.3389/fcell.2022.889002. eCollection 2022.
7
Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
Cancers (Basel). 2021 Aug 31;13(17):4402. doi: 10.3390/cancers13174402.
8
Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer.
Int J Clin Exp Pathol. 2021 Jul 15;14(7):795-810. eCollection 2021.
9
Viruses, SUMO, and immunity: the interplay between viruses and the host SUMOylation system.
J Neurovirol. 2021 Aug;27(4):531-541. doi: 10.1007/s13365-021-00995-9. Epub 2021 Aug 3.
10
SENP Proteases as Potential Targets for Cancer Therapy.
Cancers (Basel). 2021 Apr 24;13(9):2059. doi: 10.3390/cancers13092059.

本文引用的文献

1
Concepts in sumoylation: a decade on.
Nat Rev Mol Cell Biol. 2007 Dec;8(12):947-56. doi: 10.1038/nrm2293.
2
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.
Cell. 2007 Nov 2;131(3):584-95. doi: 10.1016/j.cell.2007.08.045.
3
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.
J Biol Chem. 2007 Dec 28;282(52):37341-9. doi: 10.1074/jbc.M706978200. Epub 2007 Oct 11.
4
Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells.
Free Radic Res. 2007 Jul;41(7):788-97. doi: 10.1080/10715760701361531.
5
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.
Future Oncol. 2007 Jun;3(3):329-41. doi: 10.2217/14796694.3.3.329.
6
Modification in reverse: the SUMO proteases.
Trends Biochem Sci. 2007 Jun;32(6):286-95. doi: 10.1016/j.tibs.2007.05.002. Epub 2007 May 17.
7
Role of desumoylation in the development of prostate cancer.
Neoplasia. 2006 Aug;8(8):667-76. doi: 10.1593/neo.06445.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验